drugset / Trial / NCT06415448
Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema
Summary
The purpose of the Expanded Access Program is to provide pre-approval access of donidalorsen to eligible patients with Hereditary Angioedema (HAE) who complete the ISIS 721744-CS3 clinical trial.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Donidalorsen | Antisense oligonucleotide | — | Subcutaneous |